These findings support the concept that various metabolites and relevant GPCRs function to alter Gi-PKA-SREBP signaling pathways, leading to alteration in lipid metabolism and the progression of NAFLD. This evidence concerns the gene GNAI1 and metabolic dysfunction-associated steatotic liver disease.